Results 91 to 100 of about 18,957 (200)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease [PDF]

open access: yes, 2013
This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)—for the treatment of ...
Andrzej Dekundy   +3 more
core   +1 more source

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson

open access: yesTijdschrift voor Gerontologie en Geriatrie
Casusbespreking van drie patie¨nten opgenomen in verband met hallucinaties bij de ziekte van Parkinson zonder dementie waarbij naast aanpassing van de anti-parkinson medicatie tevens wordt gestart met rivastigmine waardoor hallucinaties verdwenen en ...
jmp Rovers   +2 more
doaj   +1 more source

PMH14 HEALTH CARE EXPENDITURES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND POST TRAUMATIC STRESS DISORDER [PDF]

open access: yes, 1996
A computer model is presented that describes soleus H-reflex recruitment as a function of electric stimulus intensity. The model consists of two coupled non-linear transfer functions. The first transfer function describes the activation of muscle spindle
Bour, L. J.   +3 more
core   +1 more source

Perifériás markerek jelentősége Alzheimer-kór diagnózisában és terápiájában = Peripheral markers in the diagnosis and the therapy of Alzheimer`s disease [PDF]

open access: yes, 2006
A legjelentősebb neurokémiai abnormalitás az Alzheimer-kórban (AK) a központi idegrendszer kolinerg rendszerének csökkent működése, de feltehetőleg a perifériás szövetek is érintettek lehetnek.
Kálmán, János, Rakonczay, Zoltán
core  

2026 Alzheimer's disease facts and figures

open access: yesAlzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract This article describes the public health impact of Alzheimer's disease (AD), including prevalence and incidence, mortality and morbidity, use and costs of care, and the ramifications of AD for family caregivers, the dementia workforce, and society.
wiley   +1 more source

Review of Privileged Documents in Trial and Deposition Preparation of Witnesses in New York: When, if Ever, Will the Privilege be Lost? [PDF]

open access: yes, 2018
This article will examine New York’s refreshing recollection doctrine in the context of trial and deposition preparation of witnesses as to the consequences of the witness’s review of privileged writings.
Hutter, Michael J.
core   +1 more source

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

open access: yesClinical Interventions in Aging, 2017
Nagaendran Kandiah,1,2 Ming-Chyi Pai,3,4 Vorapun Senanarong,5 Irene Looi,6,7 Encarnita Ampil,8 Kyung Won Park,9 Ananda Krishna Karanam,10 Stephen Christopher11 1Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 2Duke-NUS,
Kandiah N   +7 more
doaj  

A prospective study on the use of rivastigmine transdermal patch in Alzheimer's dementia in a routine clinical setting

open access: yesDementia & Neuropsychologia
There is not much published literature on the use of rivastigmine patch in a "routine" clinical setting. Objectives: In this naturalistic longitudinal observational study we sought to evaluate the safety, tolerability and efficacy of the rivastigmine ...
Ejaz Nazir, Muhammad Mushtaq
doaj   +1 more source

اثربخشی ريواستيگمين در کاهش نشانه‌های حرکت‌پريشی ديررس در بيماران مبتلا به اسکيزوفرنيا [PDF]

open access: yes, 2014
هدف : هدف پژوهش حاضر بررسی اثربخشی داروی ريواستيگمين بر کاهش نشانه‌های حرکت‌پريشی ديررس (ديسکينزی تارديو) در بيماران مبتلا به اسکيزوفرنيای دريافت‌کننده داروهای ضدروان‌پريشی بود.
جهانیان, امیرعباس   +3 more
core  

Home - About - Disclaimer - Privacy